Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Isoquercetin, a glycoside form of the flavonoid quercetin, has attracted scientific interest for its potential role in supporting metabolic syndrome. Metabolic syndrome encompasses a cluster of conditions, including insulin resistance, hypertension, dyslipidemia, and central obesity, which increase the risk of cardiovascular disease and diabetes. Preclinical studies (in vitro and animal models) suggest that isoquercetin may exert beneficial effects on glucose metabolism, lipid profiles, and oxidative stress. Mechanistically, isoquercetin appears to improve insulin sensitivity, reduce inflammation, and act as an antioxidant, which are relevant pathways in metabolic syndrome.

However, clinical evidence in humans is currently limited. Several small pilot studies and randomized controlled trials have investigated quercetin or isoquercetin supplementation in populations with metabolic syndrome or its components. Some results indicate modest improvements in blood pressure, fasting glucose, and lipid parameters, but findings are inconsistent and often not statistically significant. The majority of clinical trials have focused on quercetin rather than isoquercetin specifically, and sample sizes are generally small. Comprehensive meta-analyses are lacking, and there is no consensus regarding optimal dosage, duration, or population.

Overall, while preclinical data and early human studies suggest a possible benefit of isoquercetin for metabolic syndrome, robust clinical evidence is lacking. The current scientific support is preliminary, and more large-scale, well-designed clinical trials are needed to establish efficacy and safety for this indication.

More about Isoquercetin
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Isoquercetin

Products containing Isoquercetin